- Home
- HQH vs ODTX Comparison
HQH vs ODTX Comparison
Compare HQH & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQH | ODTX |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | HQH | ODTX |
|---|---|---|
| Price | $21.80 | $24.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 179.1K | 149.1K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.36 | $15.10 |
| 52 Week High | $24.85 | $29.05 |
Technical Indicators
Market Signals| Indicator | HQH | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 49.69 |
| Support Level | $18.72 | $22.89 |
| Resistance Level | $22.29 | $28.53 |
| Average True Range (ATR) | 0.39 | 2.15 |
| MACD | -0.23 | -0.27 |
| Stochastic Oscillator | 0.19 | 14.03 |
Price Performance
Historical ComparisonAbout HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About ODTX Odyssey Therapeutics Inc. Common Stock
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.